APA (7th ed.) Citation

Swain, S. M., Kim, S., Cortés, J., Ro, J., Semiglazov, V., Campone, M., . . . Baselga, J. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The lancet. Oncology, 14(6), . https://doi.org/10.1016/S1470-2045(13)70130-X

Chicago Style (17th ed.) Citation

Swain, Sandra M., et al. "Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Study." The Lancet. Oncology 14, no. 6 (2013). https://doi.org/10.1016/S1470-2045(13)70130-X.

MLA (9th ed.) Citation

Swain, Sandra M., et al. "Pertuzumab, Trastuzumab, and Docetaxel for HER2-positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Study." The Lancet. Oncology, vol. 14, no. 6, 2013, https://doi.org/10.1016/S1470-2045(13)70130-X.